Observational studyRheumatology international2025
Prevalence and clinical features of early axial spondyloarthritis according to ASAS definition: a cross-sectional analysis from the reuma-check cohort.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Year in Review: Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives to estimate the prevalence at diagnosis of early axial spondyloarthritis in Argentinian Reuma-Check cohort, according to ASAS definition (early axSpA) and to identify clinical, laboratory, and imaging features associated with this group in a Latin American cohort. This single-center, observational, cross-sectional study included consecutive adult patients diagnosed with axSpA. Early axSpA was defined as ≤ 2 years of axial symptoms at diagnosis. Clinical, laboratory, and imaging assessments were performed following standardized protocols. A primary analysis was conducted on the entire cohort of diagnosed patients, followed by two subgroup analyses: one including only those fulfilling the ASAS 2009 criteria and another excluding patients with psoriasis. Logistic regression was conducted to identify factors independently associated with early axSpA. Among 124 patients, 38% (n = 47) had early axSpA at diagnosis. Significant differences between early and established axSpA included smoking habit (30 vs. 51%, p = 0.02), NSAID response (58 vs. 74%, p = 0.06), family history (38 vs. 23%, p = 0.04), and radiographic sacroiliitis (37 vs. 71%, p = 0.03). Logistic regression identified family history (OR: 2.4) as an independent risk factor, whereas smoking was inversely associated (OR: 0.4). Similar patterns were observed in the ASAS-fulfilling (33%) and psoriasis-excluded (36%) subgroups. At diagnosis, approximately one third of patients meet the ASAS definition of early axSpA. These patients are characterized by a higher frequency of family history, less smoking and structural damage. These results support the feasibility and relevance of future studies including patients with early axSpA to provide further scientific evidence at earlier stages of the disease.
Indexed as
Identifiers
40278897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.